Florence Joly

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.9K citations

Pharmacy, Oncology, Pharmacotherapy +14

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman, Amit M. Oza, Domenica Lorusso et al. · The Lancet · 2017 · 1.7K citations · Full text

Medicine, Gynecology, Oncology +12

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Amit M. Oza, Adrian Cook, Jacobus Pfisterer et al. · The Lancet Oncology · 2015 · 867 citations · Full text

Medicine, Gynecology, Oncology +15

Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis

David Saadoun, Michèlle Rosenzwajg, Florence Joly et al. · New England Journal of Medicine · 2011 · 746 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

Gwénaëlle Gravis, Karim Fizazi, Florence Joly et al. · The Lancet Oncology · 2013 · 740 citations

Medicine, Oncology, Urology +16